This record was last updated May 7, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks. Participants will be followed up for up to 12 weeks and will complete a daily questionnaire to self-report the consistency of response to rimegepant in acute treatment of migraine.